Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.

Abstract

DNA polymerase theta (Polθ)-mediated end joining (TMEJ) is, along with homologous recombination (HR) and non-homologous end-joining (NHEJ), one of the most important mechanisms repairing potentially lethal DNA double-strand breaks (DSBs). Polθ is becoming a new target in cancer research because it demonstrates numerous synthetically lethal interactions with other DNA repair mechanisms, e.g., those involving PARP1, BRCA1/2, DNA-PK, ATR. Inhibition of Polθ could be achieved with different methods, such as RNA interference (RNAi), CRISPR/Cas9 technology, or using small molecule inhibitors. In the context of this topic, RNAi and CRISPR/Cas9 are still more often applied in the research itself rather than clinical usage, different than small molecule inhibitors. Several Polθ inhibitors have been already generated, and two of them, novobiocin (NVB) and ART812 derivative, are being tested in clinical trials against HR-deficient tumors. In this review, we describe the significance of Polθ and the Polθ-mediated TMEJ pathway. In addition, we summarize the current state of knowledge about Polθ inhibitors and emphasize the promising role of Polθ as a therapeutic target.

• Authors: Gabriela Barszczewska-Pietraszek, Małgorzata Drzewiecka, Piotr Czarny, Tomasz Skorski, Tomasz Śliwiński
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 24 Issue 1 (Dec 24 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 36613762 (Publication Type: Journal Article, Review)

Chemical References

• DNA
• DNA polymerase theta
• Nucleic Acid Synthesis Inhibitors

Topics

• Humans
• DNA (genetics)
• DNA Breaks, Double-Stranded
• DNA End-Joining Repair
• DNA Repair
• Homologous Recombination
• Neoplasms (drug therapy, genetics)
• Nucleic Acid Synthesis Inhibitors (pharmacology)